Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

Journal of Clinical Investigation

Volumn 121, Issue 8, 2011, Pages 3100-3108

  Lesterhuis, W Joost ^a   Punt, Cornelis J A ^a   Hato, Stanleyson V ^a   Eleveld Trancikova, Dagmar ^a   Jansen, Bastiaan J H ^a   Nierkens, Stefan ^a   Schreibelt, Gerty ^a   De Boer, Annemiek ^a   Van Herpen, Carla M L ^a   Kaanders, Johannes H ^a   Van Krieken, Johan H J M ^a   Adema, Gosse J ^a   Figdor, Carl G ^a   De Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IRINOTECAN; LENALIDOMIDE; METHOTREXATE; OXALIPLATIN; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; STAT6 PROTEIN; VINCRISTINE;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; DOWN REGULATION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TH1 CELL; TUMOR MICROENVIRONMENT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CISPLATIN; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; HUMANS; IMMUNE SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASMS; PHOSPHORYLATION; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 79961016549     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43656     Document Type: Article

References (37)

1. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer. 2005;5(5):397-405. (Pubitemid 40637831)
2. Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest. 2009;119(8):2127-2130.
3. Nowak AK, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170(10):4905-4913. (Pubitemid 36554719)
4. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009;183(1):137-144.
5. Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61. (Pubitemid 46067386)
6. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-1059. (Pubitemid 47517504)
7. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8(1):74-80.
8. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003;100(9):5336-5341. (Pubitemid 36542706)
9. Liang SC, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33(10):2706-2716. (Pubitemid 37337136)
10. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. (Pubitemid 351600389)
11. Rodig N, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33(11):3117-3126. (Pubitemid 37428344)
12. Shen CH, Stavnezer J. Interaction of stat6 and NFkappaB: direct association and synergistic activation of interleukin-4-induced transcription. Mol Cell Biol. 1998;18(6):3395-3404. (Pubitemid 28240512)
13. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97-105. (Pubitemid 38198738)
14. Bakker AB, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005-1009.
15. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002;42(3):317-325. (Pubitemid 34615692)
16. Ghiringhelli F, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170-1178.
17. Ramakrishnan R, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010;120(4):1111-1124.
18. Bracci L, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res. 2007;13(2 pt 1):644-653. (Pubitemid 46225372)
19. Vincent J, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052-3061.
20. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105(7):2862-2868. (Pubitemid 40446280)
21. Zhang Y, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A. 2006;103(31):11695-11700. (Pubitemid 44182513)
22. Pfistershammer K, et al. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol. 2006;36(5):1104-1113.
23. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
24. Ohigashi Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947-2953. (Pubitemid 40525197)
25. Jacobs JF, et al. Regulatory T cells and the PDL1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11(4):394-402.
26. Hamanishi J, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360-3365. (Pubitemid 46364164)
27. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293- 12297.
28. Hirano F, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089-1096. (Pubitemid 40216472)
29. Charles KA, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119(10):3011-3023.
30. Aspord C, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007;204(5):1037-1047. (Pubitemid 46798148)
31. Lesterhuis WJ, et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol. 2006;17(6):974-980. (Pubitemid 43778989)
32. de Vries IJ, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407-1413.
33. de Vries IJ, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother. 2002;25(5):429-438.
34. den Dekker E, et al. Monocyte cell surface glycosaminoglycans positively modulate IL-4-induced differentiation toward dendritic cells. J Immunol. 2008;180(6):3680-3688.
35. Schaft N, et al. Peptide fine specificity of antiglycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol. 2003;170(4):2186-2194. (Pubitemid 36197443)
36. Schaft N, et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother. 2006;55(9):1132-1141. (Pubitemid 43800728)
37. Schreibelt G, et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood. 2010;116(4):564-574.